This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.
Age ≥18 years.
Pathologically confirmed pancreatic cancer (excluding neuroendocrine histology).
Pancreatic tumor is surgically removed and
patient has received multimodal therapy (neoadjuvant, sandwich or adjuvant chemotherapy ± radiation) or
CA 19-9 non-producers, unless high-risk pathological features present.
Receiving concomitant investigational agent(s) for pancreatic ductal adenocarcinoma (PDAC).
Radiographic evidence of metastatic disease.
Inability to ingest study drugs by mouth.
Single group
Treatment Plan
Other interventionA matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
Disease-free Survival
The number of subjects exhibiting disease-free survival at six months. Disease-free survival is defined as the time from study therapy initiation until disease recurrence or death from any cause.
Adverse Events
The number of clinically relevant Grade 3 to 4 adverse events and serious adverse events that are at least possibly related to the study therapy per investigator assessment.
Click on the lead sponsor to view all of their trials.
